Company profile: Cordis
1.1 - Company Overview
Company description
- Provider of less invasive treatments for vascular disease as a Johnson & Johnson company, and developer/manufacturer of stents, catheters, and guidewires. Offerings include SELUTION SLR Drug-Eluting Balloon for controlled, sustained sirolimus release; BRITE TIP Guiding Catheter; MYNX CONTROL Vascular Closure Device; RAIN Sheath Transradial thin-walled introducer; and RAILWAY Sheathless Access System.
Products and services
- MYNX CONTROLâ„¢ Vascular Closure Device: A resorbable device used for vascular closure, integrating active sealing and resorbability to accomplish closure
- RAILWAYâ„¢ Sheathless Access System: A sheathless access system that reduces access size and is compatible with various guiding catheters
- SELUTION SLRâ„¢ Drug-Eluting Balloon: A clinical-grade balloon catheter engineered for controlled and sustained release of sirolimus to treat vascular disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cordis
Annexin Pharmaceuticals
HQ: Sweden
Website
- Description: Provider of biotechnology focused on Annexin A5-based therapeutics. Develops ANXV, a human recombinant Annexin A5 that targets phosphatidylserine for acute treatment of cardiovascular diseases and is being investigated for retinal vein occlusion, cancer, and sickle cell disease. ANXV aims to protect cells, modulate immune responses, and reduce vascular inflammation and cellular stress.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annexin Pharmaceuticals company profile →
4C Medical
HQ: United States
Website
- Description: Provider of minimally invasive therapies for structural heart disease, including AltaValve, a transcatheter mitral valve replacement device designed to treat mitral regurgitation by positioning above the native valve, preserving cardiac structures, and accommodating complex anatomies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4C Medical company profile →
Kalila Medical
HQ: United States
Website
- Description: Provider of specialized catheters for vascular and intracardiac access, developing a platform including steerable sheaths for catheter-based atrial fibrillation ablation. Compatible with 8Fr and 12Fr ablation catheters, the Kalila sheath provides superior torque and tip.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kalila Medical company profile →
Retia Medical
HQ: United States
Website
- Description: Provider of patient monitoring software and hardware, notably the Argos Cardiac Output Monitor using a proprietary Multi-Beat Analysis algorithm for accurate, real-time cardiac output and comprehensive hemodynamic data. Offers quick setup via a single reusable cable, compatibility with arterial lines and multi-parameter monitors, integration with 40+ EMRs, and demonstrated reductions in complications and ICU stay.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retia Medical company profile →
Nanostim
HQ: United States
Website
- Description: Provider of early-stage medical device technology aimed at preventing complications related to pacemakers, addressing more than 100,000 annual incidents. The company has assembled a world-class team of experienced medical device engineers to bring this technology to market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanostim company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cordis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cordis
2.2 - Growth funds investing in similar companies to Cordis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cordis
4.2 - Public trading comparable groups for Cordis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →